Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NECTIN4 | Q96NY8 | 10/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.39 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274692 | 0.94 | CTSL (0.71) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14274695 | 0.94 | CTSL (0.68) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14274666 | 0.94 | CTSL (0.67) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL8260125 | 0.93 | CTSL (0.59) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL8258548 | 0.93 | CTSL (0.58) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14274683 | 0.92 | CTSL (0.68) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14274716 | 0.91 | CTSL (0.72) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14275199 | 0.91 | CTSL (0.57) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14274668 | 0.91 | CTSL (0.67) | CTSLDRD1PTGS1PDE4AKEAP1 | |
| SCHEMBL14274698 | 0.91 | CTSL (0.67) | CTSLDRD1PTGS1PDE4AKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | CTSL 49/4885DRD1 3359/4885PTGS1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.